Nephrology

Building Your Rare Disease Care Team

At a Glance

People with Glaudemans type hypomagnesemia often benefit from a coordinated team led by a nephrologist, with genetic, neurological, and heart specialists involved as needed. Bringing genetic reports, paired lab results, medications, symptoms, and imaging helps each clinician understand the condition.

Because Glaudemans Type Hypomagnesemia is an “ultra-rare” condition, you will likely not find a single doctor who is already an expert in it. Instead, your goal is to build a multidisciplinary team of specialists who are curious, collaborative, and willing to learn alongside you ^[1]^[2].

The Core Specialists

A rare genetic disorder that affects both the kidneys and the nervous system requires expertise from several different fields ^[3]^[4].

The Nephrologist (The Lead): Since the primary issue is magnesium “wasting” through the kidneys, a nephrologist who specializes in tubulopathies (disorders of the kidney’s filtering tubes) should be your primary point of contact ^[5]^[6]. They will manage your electrolyte supplements, monitor your kidney function over time, and watch for complications like kidney stones ^[6]^[7].
The Medical Geneticist: A geneticist and a genetic counselor are essential for interpreting your specific KCNA1 mutation ^[3]. They can explain the variant’s classification, help coordinate testing for family members, and discuss the 50% chance of passing the variant to children ^[8]^[9].
The Neurologist: Because the KCNA1 gene is also active in your brain and nerves, you may experience symptoms like twitching (myokymia) or balance issues (ataxia) that aren’t just caused by low magnesium ^[10]^[11]. A neurologist can help determine if these symptoms are a direct effect of the gene mutation and if they require specific neurological treatments ^[12]^[13].
The Cardiologist: Significant electrolyte imbalances can affect your heart rhythm. A cardiologist may be needed to review your EKG, especially to monitor your QT interval, which can be affected by low magnesium ^[14]^[15].

Your “First Visit” Checklist

When meeting a new specialist, having your information organized can save time and help them focus on your specific needs. Bring the following items to every first-time consultation:

The Genetic Report: This is the most important document you own. It lists the exact “address” of your mutation which helps the doctor look up the correct research ^[16]^[17].
Paired Lab Results: If you have them, bring blood and urine tests that were taken on the same day. These are used to calculate your Fractional Excretion of Magnesium (FEMg) ^[7]^[18].
Medication Log: Include every supplement you take, the exact dose (in milligrams), and how many times a day you take it ^[19].
Symptom Timeline: A brief history of when your symptoms started and what triggers them (such as stress, exercise, or heat) ^[17]^[13].
Relevant Prior Imaging: Bring any prior renal imaging if it has already been performed or is clinically relevant ^[20].

Vetting Your Team

In the world of rare disease, a “good” doctor is one who admits what they don’t know but is committed to finding out ^[21]. You are looking for a clinician who views you as a partner in care. If a doctor dismisses your research or is unwilling to coordinate with your other specialists, they may not be the right fit for managing a complex, multi-system genetic condition ^[22]. Instead, look for specialists who are connected to rare-kidney networks or university research centers ^[23].

Common questions in this guide

Which specialists should be involved in care for Glaudemans type hypomagnesemia?

A nephrologist, especially one familiar with kidney tubule disorders, is often the main point of contact for magnesium loss and kidney monitoring. A medical geneticist and genetic counselor can explain the KCNA1 variant, while a neurologist or cardiologist may be involved when nerve symptoms or heart-rhythm concerns are present.

What should I bring to my first appointment with a rare-disease specialist?

Bring your genetic report, blood and urine results collected on the same day when available, a complete medication and supplement list, a symptom timeline, and relevant kidney imaging. These records help the team understand your magnesium loss, symptoms, treatment, and previous evaluation.

Why is a nephrologist important for this condition?

Glaudemans type hypomagnesemia can cause the kidneys to lose too much magnesium. A nephrologist can manage electrolyte supplements, monitor kidney function, and watch for complications such as kidney stones.

Can KCNA1-related hypomagnesemia cause neurological symptoms?

The KCNA1 gene is active in the brain and nerves, so some people may have muscle twitching or balance problems in addition to symptoms related to low magnesium. A neurologist can help determine whether these symptoms are related to the gene variant and whether they need additional treatment.

Should I ask for a written emergency plan?

Yes. Ask your care team whether a written plan should explain your KCNA1 diagnosis, usual electrolyte levels, current supplements, and who to contact, so emergency clinicians have important background information.

How can I find doctors who are prepared to manage this rare condition?

Look for clinicians connected with a rare-kidney network, renal-genetics program, or university research center. A good care team should be willing to collaborate, review current information, and coordinate with your other specialists.

Get notified when new evidence is published on Isolated autosomal dominant hypomagnesemia, Glaudemans type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (23)

1
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope.
Groothoff JW, Metry E, Deesker L, et al.
Nature reviews. Nephrology 2023; (19(3)):194-211 doi:10.1038/s41581-022-00661-1.
PMID: 36604599
2
Lessons learned from a multidisciplinary renal genetics clinic.
Alkanderi S, Yates LM, Johnson SA, Sayer JA
QJM : monthly journal of the Association of Physicians 2017; (110(7)):453-457 doi:10.1093/qjmed/hcx030.
PMID: 28177086
3
Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies.
Ashton EJ, Legrand A, Benoit V, et al.
Kidney international 2018; (93(4)):961-967 doi:10.1016/j.kint.2017.10.016.
PMID: 29398133
4
Diagnosis and Treatment of Hypophosphatasia.
Seefried L, Genest F, Hofmann C, et al.
Calcified tissue international 2025; (116(1)):46 doi:10.1007/s00223-025-01356-y.
PMID: 40047955
5
[Expert consensus for the diagnosis and treatment of patients with Gitelman syndrome].

Zhonghua nei ke za zhi 2017; (56(9)):712-716 doi:10.3760/cma.j.issn.0578-1426.2017.09.021.
PMID: 28870047
6
How to Suspect and Approach Patients With Genetic Tubular Disease.
Karet Frankl FE
Seminars in nephrology 2025; (45(4)):151654 doi:10.1016/j.semnephrol.2025.151654.
PMID: 40681419
7
Utility of fractional excretion of magnesium in diagnosing renal magnesium wasting in pediatric nephrology practice.
Awazu M, Matsumura K
Clinical biochemistry 2024; (131-132()):110807 doi:10.1016/j.clinbiochem.2024.110807.
PMID: 39059606
8
Ultra-rare renal diseases diagnosed with whole-exome sequencing: Utility in diagnosis and management.
Jung J, Lee JH, Park YS, et al.
BMC medical genomics 2021; (14(1)):177 doi:10.1186/s12920-021-01026-6.
PMID: 34217267
9
Clinical Spectrum of KCNA1 Mutations: New Insights into Episodic Ataxia and Epilepsy Comorbidity.
Paulhus K, Ammerman L, Glasscock E
International journal of molecular sciences 2020; (21(8)) doi:10.3390/ijms21082802.
PMID: 32316562
10
Therapeutic Potential of Sodium Channel Blockers as a Targeted Therapy Approach in KCNA1-Associated Episodic Ataxia and a Comprehensive Review of the Literature.
Lauxmann S, Sonnenberg L, Koch NA, et al.
Frontiers in neurology 2021; (12()):703970 doi:10.3389/fneur.2021.703970.
PMID: 34566847
11
New insights into the pathogenesis and therapeutics of episodic ataxia type 1.
D'Adamo MC, Hasan S, Guglielmi L, et al.
Frontiers in cellular neuroscience 2015; (9()):317 doi:10.3389/fncel.2015.00317.
PMID: 26347608
12
Musculoskeletal Features without Ataxia Associated with a Novel de novo Mutation in KCNA1 Impairing the Voltage Sensitivity of Kv1.1 Channel.
Imbrici P, Accogli A, Blunck R, et al.
Biomedicines 2021; (9(1)) doi:10.3390/biomedicines9010075.
PMID: 33466780
13
Two novel KCNA1 variants identified in two unrelated Chinese families affected by episodic ataxia type 1 and neurodevelopmental disorders.
Yuan H, Yuan H, Wang Q, et al.
Molecular genetics & genomic medicine 2020; (8(10)):e1434 doi:10.1002/mgg3.1434.
PMID: 32705822
14
Atrial Flutter-Triggered Ventricular Tachycardia Storm in Gitelman Syndrome: A Case Report.
Elganainy M, Hammami AS, Peltz J, Oriaifo OF
Cureus 2026; (18(6)):e110146 doi:10.7759/cureus.110146.
PMID: 42403806
15
Vonoprazan-associated hypomagnesemia presenting to the emergency department with altered mental status and a suspected seizure.
Okamoto N, Onishi S, Manabe T, et al.
The American journal of emergency medicine 2026; (101()):131-134 doi:10.1016/j.ajem.2025.12.034.
PMID: 41512442
16
Novel CNNM2 variant causing hypomagnesemia and early-onset calcium pyrophosphate deposition disease: A case report.
Robert C, Perrot L, Zelus A, et al.
Joint bone spine 2026; (93(1)):105982 doi:10.1016/j.jbspin.2025.105982.
PMID: 41022172
17
A de novo KCNA1 Mutation in a Patient with Tetany and Hypomagnesemia.
van der Wijst J, Konrad M, Verkaart SAJ, et al.
Nephron 2018; (139(4)):359-366 doi:10.1159/000488954.
PMID: 29791908
18
Clinical and genetic approach to renal hypomagnesemia.
Tseng MH, Konrad M, Ding JJ, Lin SH
Biomedical journal 2022; (45(1)):74-87 doi:10.1016/j.bj.2021.11.002.
PMID: 34767995
19
Neuromuscular tetanic hyperexcitability syndrome associated to a heterozygous Kv1.1 N255D mutation with normal serum magnesium levels.
Bianchi F, Simoncini C, Brugnoni R, et al.
Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology 2020; (39(1)):36-39 doi:10.36185/2532-1900-007.
PMID: 32607479
20
Spectrum of neuro-genetic disorders in the United Arab Emirates national population.
Saleh S, Beyyumi E, Al Kaabi A, et al.
Clinical genetics 2021; (100(5)):573-600 doi:10.1111/cge.14044.
PMID: 34374989
21
Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey.
Stepien KM, Kieć-Wilk B, Lampe C, et al.
Frontiers in medicine 2021; (8()):652358 doi:10.3389/fmed.2021.652358.
PMID: 33738294
22
Transition of patients with mucopolysaccharidosis from paediatric to adult care.
Lampe C, McNelly B, Gevorkian AK, et al.
Molecular genetics and metabolism reports 2019; (21()):100508 doi:10.1016/j.ymgmr.2019.100508.
PMID: 31687335
23
Rare Disease Registries Are Key to Evidence-Based Personalized Medicine: Highlighting the European Experience.
Kölker S, Gleich F, Mütze U, Opladen T
Frontiers in endocrinology 2022; (13()):832063 doi:10.3389/fendo.2022.832063.
PMID: 35317224

This page is for education about assembling a care team for Glaudemans type hypomagnesemia and does not replace medical advice. Your nephrologist, geneticist, neurologist, and other clinicians can tailor monitoring and treatment to your situation.